Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004

Journal of Public Health

Volumn 29, Issue 1, 2007, Pages 48-52

  Patel, Hitesh ^a   Srishanmuganathan, Janakan ^b   Car, Josip ^c   Majeed, Azeem ^c  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Costs and cost analysis; Diabetes mellitus; Drug costs; Economics; Pharmaceutical preparations

Indexed keywords

EID: 33847418001     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fdl076     Document Type: Article

References (23)

1. Department of Health. National Service Frameworks for Diabetes: Standards. Department of Health, London, 2001.
2. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(Suppl. 5):S1-85.
3. Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.
4. Bell D. Stroke in the diabetic patient. Diabetes Care 1994;17:213-9.
5. Bild D, Selby J, Sinnock P et al. Lower-extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care 1989;12:24-31.
6. Christensen P, Rossing P, Nielsen F et al. Natural course of kidney function in type 2 diabetic patients with diabetic nephropathy. Diabet Med 1999;16:388-94.
7. Evans J. Causes of Blindness and Partial Sight in England and Wales, 1990-1991. Office of Population Censuses and Surveys, Studies on Medical and Population Subjects, No. 57. London: HMSO, 1995.
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
9. UKPDS Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
10. The Association of British Pharmaceutical Industry. http:// www.abpi.org.uk (July 2006, date last accessed).
11. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
12. British Heart Foundation Statistics Webpage. http://www.heartstats.org (July 2006, date last accessed).
13. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
14. National Institute of Clinical Excellence. Management of Type 2 Diabetes. Management of Blood Glucose. London: National Institute for Clinical Excellence, September 2002.
15. National Institute for Clinical Excellence. Guidance on the Use of Glitazones for Type 2 Diabetes Mellitus. NICE Technology Appraisal Guidance No. 63. London: National Institute for Clinical Excellence, August 2003.
16. Parulkar A, Pendergrass M, Granda-Ayala R et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
17. Van de Laar F, Lucassen P, Akkermans R et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 (Issue 2). Art. no. CD003639.
18. Coster S, Gulliford M, Seed P et al. Monitoring blood glucose control in diabetes mellitus: a systematic review. Health Technol Assess 2000;4(12):1-93.
19. Franciosi M, Pellegrini F, De Beradis G et al. Impact of blood glucose monitoring on metabolic control and quality of life in type 2 diabetic patients. Diabetes Care 2001;24:1870-7.
20. Reunanen A, Martikainen J, Kangas T et al. Nationwide survey of comorbidity, use and costs of all medications in Finnish diabetic individuals. Diabetes Care 2000;23:1265-71.
21. Wandell P, Gafvels C. Drug prescription in men and women with type 2 diabetes in Stockholm in 1995 and 2001: change over time. Eur J Clin Pharmacol 2002;58:547-53.
22. Jonsson B. CODE-2 advisory board. Revealing the cost of type II diabetes in Europe. Diabetologica 2002;45:S5-12.
23. Majeed A, Evans N, Head P. What can PACT tell us about prescribing in general practice? BMJ 1997;315:1515-9.